Basic Information
COMIRNATY ORIGINAL/OMICRON BA.4-5 DISPERSION FOR INJECTION 15/15 MICROGRAMS/DOSE (MULTI-DOSE VIAL)
INJECTION
Regulatory Information
SIN16855P
September 7, 2023
Prescription Only
Therapeutic
INTRAMUSCULAR
January 24, 2024
May 30, 2025
XJ07BN01
Company Information
BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
Active Ingredients
Strength: 15 μg/dose
Strength: 15 μg/dose
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** COMIRNATY (Bivalent) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.